OXiGENE Announces Presentation Of Data From Preclinical Study Of ZYBRESTAT

(RTTNews) - OXiGENE, Inc.(OXGN), announced the presentation of data from a preclinical study of ZYBRESTAT, demonstrating significant antitumor activity in pancreatic neuroendocrine tumor model. This study was designed to evaluate the efficacy of systemic administration of ZYBRESTAT or CA4P for the treatment of functional insulinomas in a transgenic mouse model of pancreatic neuroendocrine tumors or PNETs, which are highly vascularized tumors which originate in the pancreas. These data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, on October 20.

The treatment group received ZYBRESTAT three times per week for four weeks, and the control group received a placebo. Key results were that treatment with ZYBRESTAT resulted in a significant and sustained decrease in circulating insulin, and the a significantly reduced tumor size in the treated group compared to the placebo group. Also, treatment with ZYBRESTAT was shown to disrupt tumor vasculature, induce apoptosis and inhibit tumor cell proliferation. ZYBRESTAT was shown to be well tolerated, with no obvious toxicity.